Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
May 28, 2024 06:30 ET
|
G1 Therapeutics
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 ADC
Urteste has successfully developed a prototype urine-based diagnostic test for detecting brain tumours
May 28, 2024 06:24 ET
|
Urteste S.A.
28 MAY 2024 PRESS RELEASE Urteste has successfully developed a prototype urine-based diagnostic test for detecting brain tumours Gdańsk, Poland – 28 MAY 2024, Urteste S.A. (Warsaw Stock...
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
May 24, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024
May 23, 2024 02:00 ET
|
Burning Rock Biotech Limited
Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024
[Latest] Global Non-Small-Cell Lung Cancer Drug Market Size/Share Worth USD 68,888.6 Million by 2033 at a 8.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 21, 2024 03:30 ET
|
Custom Market Insights
Austin, TX, USA, May 21, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Non-Small-Cell Lung Cancer Drug Market Size, Trends and Insights By Cancer Type...
[Latest] Global Colorectal Cancer Market Size/Share Worth USD 30,095.9 Million by 2033 at a 3.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 20, 2024 12:30 ET
|
Custom Market Insights
Austin, TX, USA, May 20, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Colorectal Cancer Market Size, Trends and Insights By Type of Treatment (Surgery,...
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
May 20, 2024 09:15 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that AIM Chief Executive Officer Thomas K. Equels will participate in...
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 16, 2024 07:30 ET
|
AIM ImmunoTech Inc.
Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference call and webcast today, May...
Health Canada Approves Saladax’s 5-Fluorouracil Chemotherapy Therapeutic Drug Monitoring (TDM) Test
May 14, 2024 10:00 ET
|
Saladax Biomedical, Inc.
Bethlehem, PA, May 14, 2024 (GLOBE NEWSWIRE) -- Saladax Biomedical, Inc. (Saladax) is pleased to announce that Health Canada has approved Saladax’s 5-Fluorouracil (My5-FU) Assay for sale in Canada...
Burning Rock Announces ADS Ratio Change to Be Effective on May 15, 2024
May 14, 2024 02:02 ET
|
Burning Rock Biotech Limited
Burning Rock Announces ADS Ratio Change to Be Effective on May 15, 2024